Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP3 | P08254 | 4/20 | 0.43 |
| ▸ | MMP13 | P45452 | 4/20 | 0.43 |
| ▸ | MMP2 | P08253 | 4/20 | 0.43 |
| ▸ | MMP1 | P03956 | 3/20 | 0.43 |
| ▸ | MMP8 | P22894 | 2/20 | 0.43 |
| ▸ | MMP12 | P39900 | 2/20 | 0.43 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.43 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5053273 | 0.88 | ADAMTS4 (0.45) | — | |
| SCHEMBL5053089 | 0.83 | GRM3 (0.50) | — | |
| SCHEMBL7607893 | 0.81 | GRM3 (0.48) | — | |
| SCHEMBL5134279 | 0.80 | MMP13 (0.60) | MMP3MMP13MMP2MMP1MMP8 | |
| SCHEMBL7608852 | 0.79 | MMP13 (0.49) | MMP3MMP13MMP2MMP1MMP8 | |
| SCHEMBL7607361 | 0.76 | IDO1 (0.43) | — | |
| SCHEMBL7609383 | 0.75 | MMP13 (0.48) | MMP3MMP13MMP2MMP1MMP8 | |
| SCHEMBL5054484 | 0.75 | ANPEP (0.48) | — | |
| SCHEMBL5058107 | 0.74 | CYP1A2 (0.61) | — | |
| SCHEMBL5057879 | 0.74 | ADAMTS4 (0.41) | MTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1005348-A1 | NAALADASE COMPOSITIONS AND METHODS FOR TREATING GLUTAMATE ABNORMALITY AND EFFECTING NEURONAL ACTIVITY IN ANIMALS | GUILFORD PHARMACEUTICALS INC. (US) | 2000-06-07 | — | — | EP | disclosed |
| WO-1998013046-A1 | NAALADASE COMPOSITIONS AND METHODS FOR TREATING GLUTAMATE ABNORMALITY AND EFFECTING NEURONAL ACTIVITY IN ANIMALS | GUILFORD PHARMACEUTICALS INC. (US) | 1998-04-02 | — | — | WO | disclosed |